NASDAQ:VTGN

Vistagen Therapeutics Stock News

Healthcare > Biotechnology

Buy VTGN

*Your capital is at risk

$0.229

-0.0108 (-4.50%)

At Close: Jul 17, 2026

VistaGen Therapeutics Announces Pricing of Underwritten Public Offering

06:25am, Friday, 18'th Dec 2020

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potent

VistaGen Therapeutics Announces Proposed Underwritten Public Offering

04:01pm, Thursday, 17'th Dec 2020

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potent

VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress

05:25pm, Thursday, 12'th Nov 2020

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other centr

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by